| # | Drug | Count |
|---|---|---|
| 0 | LETROZOLE | 181 |
| 1 | LETROZOLE TABLETS | 167 |
| 2 | FULVESTRANT | 166 |
| 3 | CAPECITABINE | 115 |
| 4 | PALBOCICLIB | 102 |
| 5 | PACLITAXEL | 89 |
| 6 | RIBOCICLIB | 89 |
| 7 | EXEMESTANE | 83 |
| 8 | DENOSUMAB | 76 |
| 9 | EVEROLIMUS | 68 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DEXTROMETHORPHAN HBR, GUAIFENESIN, PHENYLEPHRINE HCL | 4 | 0.0101 |
| 1 | VINORELBINE | 43 | 0.0062 |
| 2 | FULVESTRANT | 166 | 0.0050 |
| 3 | ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL | 4 | 0.0042 |
| 4 | GOSERELIN | 55 | 0.0041 |
| 5 | EXEMESTANE | 83 | 0.0039 |
| 6 | IBANDRONATE SODIUM | 11 | 0.0035 |
| 7 | LETROZOLE TABLETS | 167 | 0.0034 |
| 8 | EVEROLIMUS TABLETS | 56 | 0.0033 |
| 9 | LETROZOLE | 181 | 0.0029 |
| # | Drug class | Count |
|---|---|---|
| 0 | Aromatase Inhibitor [EPC] | 218 |
| 1 | Estrogen Receptor Antagonist [EPC] | 167 |
| 2 | Kinase Inhibitor [EPC] | 154 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 127 |
| 4 | Microtubule Inhibitor [EPC] | 99 |
| 5 | RANK Ligand Inhibitor [EPC] | 76 |
| 6 | mTOR Inhibitor Immunosuppressant [EPC] | 71 |
| 7 | Platinum-based Drug [EPC] | 43 |
| 8 | Alkylating Drug [EPC] | 35 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 26 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Estrogen Receptor Antagonist [EPC] | 167 | 0.0041 |
| 1 | Aromatase Inhibitor [EPC] | 218 | 0.0019 |
| 2 | Microtubule Inhibitor [EPC] | 99 | 0.0006 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 127 | 0.0005 |
| 4 | RANK Ligand Inhibitor [EPC] | 76 | 0.0004 |
| 5 | Kinase Inhibitor [EPC] | 154 | 0.0003 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 18 | 0.0002 |
| 7 | Epidermal Growth Factor Receptor Antagonist [EPC] | 8 | 0.0002 |
| 8 | Platinum-based Drug [EPC] | 43 | 0.0002 |
| 9 | Alkylating Drug [EPC] | 35 | 0.0001 |